Nano mRNA Co., Ltd. (4571) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nano mRNA Co., Ltd. (4571:JPX), powered by AI.

Current Price
¥105
P/E Ratio
-8.9
Market Cap
7.4B
Sector
Healthcare
What is the Nano mRNA Co., Ltd. stock price forecast?

Nano mRNA Co., Ltd. is currently trading at ¥105. View real-time AI analysis on Alpha Lenz.

What is Nano mRNA Co., Ltd. insider trading activity?

View the latest insider trading data for Nano mRNA Co., Ltd. on Alpha Lenz.

What is Nano mRNA Co., Ltd.'s P/E ratio?

Nano mRNA Co., Ltd.'s P/E ratio is -8.9.

Nano mRNA Co., Ltd.

JPX · 4571
¥105+7(+7.14%)Market closedJPX regular session 09:00–15:00 JST
Ask about Nano mRNA Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Nano mRNA Co., Ltd. trades at a P/E of -8.9 (undervalued) with modest ROE of -27.1%.

Ask for details

Company Overview

Nano mRNA Co., Ltd. is a prominent player in the biotechnology sector, specializing in the development and commercialization of mRNA-based therapeutics. The company's primary function is to harness the power of messenger RNA to create innovative healthcare solutions, particularly focusing on vaccines and treatments for cancer, infectious diseases, and rare genetic disorders. By translating mRNA technology into practical medical applications, Nano mRNA Co., Ltd. aims to address some of the most pressing health challenges globally. Notable features of the company include its advanced research and development facilities and strategic partnerships with academic institutions and pharmaceutical companies, which bolster its innovation capabilities. The company’s expertise in mRNA technology places it at the forefront of the rapidly evolving biotech industry, a sector characterized by its significant research investments and high regulatory standards. In the financial market, Nano mRNA Co., Ltd. holds a significant position due to its cutting-edge contributions to modern medicine and potential for growth amidst the increasing acceptance and application of mRNA technology across various therapeutic areas.

CEODr. Shiro Akinaga Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees20

Company Statistics

FY 2025

Profile

¥7,402,101,315Market Cap
¥108,516,000Revenue
0.00Shares Out
20Employees

Margins

72.03%Gross
-562.39%EBITDA
-696.07%Operating
-767.25%Pre-Tax
-769.82%Net

Valuation

-8.86P/E
2.70P/B
68.21EV/Sales
-10.22EV/EBITDA
-18.43P/FCF

Growth (CAGR)

-25.65%Rev 3Yr
-27.80%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-18.42%ROA
-27.12%ROE
-16.66%ROIC

Financial Health

¥1,707,452,000Cash & Cash Equivalents
¥-450,399,000Net Debt
45.88%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Nano mRNA Co., Ltd. (ticker: 4571) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 20 employees. Market cap is $7.4B.

The current price is 105 with a P/E ratio of -8.86x and P/B of 2.7x.

ROE is -27.12% and operating margin is -696.07%. Annual revenue is $109M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Nano mRNA Co., Ltd. (4571) Stock Forecast 2026 ¥105 — Price, Financials & Analyst Targets | Alpha Lenz